France Drug Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the France drug delivery devices market size was valued at USD 6.90 billion in 2025 and estimated to grow from USD 7.52 billion in 2026 to reach USD 11.51 billion by 2031, at a CAGR of 8.92% during the forecast period (2026-2031).

This report is Segmented by Device Type (Injectable Delivery Devices, Inhalation Delivery Devices, Infusion Pumps and More), Route of Administration (Injectable, Inhalational, Transdermal and More), Application (Diabetes, Oncology, Cardiovascular Diseases and More), End User (Hospitals, Ambulatory Surgical & Specialty Clinics and More). The Market and Forecasts are Provided in Terms of Value (USD).

France Drug Delivery Devices Market Trends and Insights

Shift to Home-Based Care & Self-Administration

France is prioritizing homecare, and the end-user segment already shows a 13.03% CAGR, the highest across settings. The National eHealth Roadmap (2023-2027) backs connected devices that transmit real-time dosing data and support remote consultations.Sanofi's Solosmart sensor, available in 21,000 pharmacies, captures insulin injection records and integrates seamlessly with patient apps. Such devices redefine competition by elevating usability and data connectivity to the same level as pharmacological performance, driving France drug delivery devices market adoption.

Expansion of Biologic & Biosimilar Injectables

High-viscosity biologics need specialized delivery formats. Novo Nordisk invested €2.1 billion in its Chartres site to double insulin capacity. BD's Neopak XtraFlow syringe targets these formulations, highlighting collaborative innovation between pharma and device makers. Growing biologic pipelines ensure sustained demand in the France drug delivery devices market, particularly for self-injectors and wearable pumps.

Complex Reimbursement Price Caps

France differentiates device and service payments and caps distributor margins, extending the average approval-to-reimbursement period to 12.9 months, compared with 6 months in Switzerland and 7.4 months in Germany. The SMR/ASMR scoring method can exclude low-benefit products from coverage, slowing revenue for combination devices and tempering growth within the France drug delivery devices market.

Other drivers and restraints analyzed in the detailed report include:

1. Technological Advancements and e-Health Strategy
2. Robust CDMO & Device Manufacturing Ecosystem
3. Stringent Regulatory Framework

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Injectables retained 45.02% share in 2025, supported by steady biologic usage and continuous upgrades in prefilled syringes and autoinjectors. BD's RFID-enabled iDFill syringe shown at Pharmapack 2025 underscores a focus on traceability and patient safety. Despite this lead, implantables are forecast to rise at 11.32% CAGR to 2031, reflecting patient preference for longer dosing intervals and emerging hydrogel reservoirs that stretch semaglutide dosing to monthly schedules. This momentum positions implantables as a disruptive force inside the France drug delivery devices market.

Transdermal patches, ocular inserts, and intranasal systems broaden therapeutic choices. The nasal route, highlighted by Pfizer's approved Zavzpret spray for migraine, demonstrates expanding utility beyond respiratory therapy. These additive modalities bolster device diversity and reinforce overall resilience of the France drug delivery devices market.

Injectables accounted for 57.55% of France drug delivery devices market size in 2025, favored for precision dosing across chronic illnesses. Continuous needle-design refinements improve user comfort, strengthening retention in both hospital and home settings.

Inhalation is slated for 9.24% CAGR between 2026-2031. Partnerships such as Chiesi-Affibody on inhaled biologics widen respiratory portfolios. Nasal delivery gains traction for central nervous system targets; French start-up Lovaltech advances an intranasal vaccine platform under France 2030 funding. These advances expand treatment horizons and feed sustained growth within the France drug delivery devices market.

Complete Report Scope:

• By Device Type
  • Injectable Delivery Devices
  • Inhalation Delivery Devices
  • Infusion Pumps
  • Transdermal Patches
  • Implantable Drug Delivery Systems
  • Ocular Inserts & Delivery Implants
  • Nasal & Buccal Delivery Devices
• By Route of Administration
  • Injectable
  • Inhalation
  • Transdermal
  • Oral Mucosal (Buccal & Sublingual)
  • Ocular
  • Nasal
• By Application
  • Diabetes
  • Oncology
  • Cardiovascular Diseases
  • Respiratory Diseases
  • Infectious Diseases
  • Auto-Immune & Inflammatory Disorders
  • CNS Disorders
• By End User
  • Hospitals
  • Ambulatory Surgical & Specialty Clinics
  • Homecare Settings / Self-Use
  • Retail & Online Pharmacies

List of Companies Covered in this Report:

1. Sanofi
2. Beckton Dickinson
3. Roche
4. Novo Nordisk
5. Johnson & Johnson
6. Solventum
7. Baxter
8. Bayer
9. Pfizer
10. Terumo
11. Gerresheimer
12. Nemera
13. AptarGroup, Inc.
14. West Pharmaceutical Services
15. Ypsomed
16. Vetter Pharma-Fertigung
17. B. Braun
18. Owen Mumford
19. Insulet
20. Tandem Diabetes Care
21. Eli Lilly and Company
22. Recipharm
23. Unither Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support